Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study. / Horsbøl, Trine Allerslev; Kjaer, Susanne K.; Andersen, Elisabeth Wreford; Ammitzbøll, Gunn; Thygesen, Lau Caspar; Johansen, Christoffer; Jensen, Pernille Tine; Frøding, Ligita Paskeviciute; Lajer, Henrik; Dalton, Susanne Oksbjerg.

I: Gynecologic Oncology, Bind 166, Nr. 2, 2022, s. 300-307.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Horsbøl, TA, Kjaer, SK, Andersen, EW, Ammitzbøll, G, Thygesen, LC, Johansen, C, Jensen, PT, Frøding, LP, Lajer, H & Dalton, SO 2022, 'Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study', Gynecologic Oncology, bind 166, nr. 2, s. 300-307. https://doi.org/10.1016/j.ygyno.2022.05.019

APA

Horsbøl, T. A., Kjaer, S. K., Andersen, E. W., Ammitzbøll, G., Thygesen, L. C., Johansen, C., Jensen, P. T., Frøding, L. P., Lajer, H., & Dalton, S. O. (2022). Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study. Gynecologic Oncology, 166(2), 300-307. https://doi.org/10.1016/j.ygyno.2022.05.019

Vancouver

Horsbøl TA, Kjaer SK, Andersen EW, Ammitzbøll G, Thygesen LC, Johansen C o.a. Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study. Gynecologic Oncology. 2022;166(2):300-307. https://doi.org/10.1016/j.ygyno.2022.05.019

Author

Horsbøl, Trine Allerslev ; Kjaer, Susanne K. ; Andersen, Elisabeth Wreford ; Ammitzbøll, Gunn ; Thygesen, Lau Caspar ; Johansen, Christoffer ; Jensen, Pernille Tine ; Frøding, Ligita Paskeviciute ; Lajer, Henrik ; Dalton, Susanne Oksbjerg. / Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study. I: Gynecologic Oncology. 2022 ; Bind 166, Nr. 2. s. 300-307.

Bibtex

@article{84bdfb6b1e6244919285aa8eccec4139,

title = "Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study",

abstract = "Objective: Previous studies suggest that sleeping problems are frequent after cervical cancer. However, the evidence on the use of hypnotics is sparse. We investigated if women diagnosed with cervical cancer have an increased risk of using hypnotics and identified risk factors for prolonged use. Methods: In this nationwide register-based cohort study, 4264 women diagnosed with cervical cancer from 1997 to 2013 and 36,632 cancer-free women were followed in registers until 2016. Prolonged use of hypnotics was defined as more than three prescriptions with no more than three months in between. Data were analysed using Cox proportional hazards regression models and multistate Markov models separately for women with localized and advanced cervical cancer. Results: The rate of first use of hypnotics was substantially increased during the first year after cervical cancer diagnosis compared to cancer-free women (HRlocalized 4.4, 95% CI 3.9–5.1; HRadvanced 8.9, 95% CI 7.5–10.6) and remained markedly increased for up to five years after diagnosis. Dependent on stage of disease and age, 1.4 to 4.7 excess women per 100 with cervical cancer were prolonged users of hypnotics compared to cancer-free women one year after diagnosis. Risk factors for prolonged use of hypnotics were higher age, short education, previous use of antidepressants or anxiolytics, and advanced disease. Conclusions: Women diagnosed with cervical cancer are at increased risk of prolonged use of hypnotics. For the majority, treatment with hypnotics is initiated within the first year after cancer diagnosis, but the rate of first use is increased for up to five years.",

keywords = "Cervical cancer, Cohort study, Epidemiology, Hypnotic use, Late effects, Sleeping problems",

author = "Horsb{\o}l, {Trine Allerslev} and Kjaer, {Susanne K.} and Andersen, {Elisabeth Wreford} and Gunn Ammitzb{\o}ll and Thygesen, {Lau Caspar} and Christoffer Johansen and Jensen, {Pernille Tine} and Fr{\o}ding, {Ligita Paskeviciute} and Henrik Lajer and Dalton, {Susanne Oksbjerg}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

doi = "10.1016/j.ygyno.2022.05.019",

language = "English",

volume = "166",

pages = "300--307",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press",

number = "2",

}

RIS

TY - JOUR

T1 - Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study

AU - Horsbøl, Trine Allerslev

AU - Kjaer, Susanne K.

AU - Andersen, Elisabeth Wreford

AU - Ammitzbøll, Gunn

AU - Thygesen, Lau Caspar

AU - Johansen, Christoffer

AU - Jensen, Pernille Tine

AU - Frøding, Ligita Paskeviciute

AU - Lajer, Henrik

AU - Dalton, Susanne Oksbjerg

PY - 2022

Y1 - 2022

N2 - Objective: Previous studies suggest that sleeping problems are frequent after cervical cancer. However, the evidence on the use of hypnotics is sparse. We investigated if women diagnosed with cervical cancer have an increased risk of using hypnotics and identified risk factors for prolonged use. Methods: In this nationwide register-based cohort study, 4264 women diagnosed with cervical cancer from 1997 to 2013 and 36,632 cancer-free women were followed in registers until 2016. Prolonged use of hypnotics was defined as more than three prescriptions with no more than three months in between. Data were analysed using Cox proportional hazards regression models and multistate Markov models separately for women with localized and advanced cervical cancer. Results: The rate of first use of hypnotics was substantially increased during the first year after cervical cancer diagnosis compared to cancer-free women (HRlocalized 4.4, 95% CI 3.9–5.1; HRadvanced 8.9, 95% CI 7.5–10.6) and remained markedly increased for up to five years after diagnosis. Dependent on stage of disease and age, 1.4 to 4.7 excess women per 100 with cervical cancer were prolonged users of hypnotics compared to cancer-free women one year after diagnosis. Risk factors for prolonged use of hypnotics were higher age, short education, previous use of antidepressants or anxiolytics, and advanced disease. Conclusions: Women diagnosed with cervical cancer are at increased risk of prolonged use of hypnotics. For the majority, treatment with hypnotics is initiated within the first year after cancer diagnosis, but the rate of first use is increased for up to five years.

AB - Objective: Previous studies suggest that sleeping problems are frequent after cervical cancer. However, the evidence on the use of hypnotics is sparse. We investigated if women diagnosed with cervical cancer have an increased risk of using hypnotics and identified risk factors for prolonged use. Methods: In this nationwide register-based cohort study, 4264 women diagnosed with cervical cancer from 1997 to 2013 and 36,632 cancer-free women were followed in registers until 2016. Prolonged use of hypnotics was defined as more than three prescriptions with no more than three months in between. Data were analysed using Cox proportional hazards regression models and multistate Markov models separately for women with localized and advanced cervical cancer. Results: The rate of first use of hypnotics was substantially increased during the first year after cervical cancer diagnosis compared to cancer-free women (HRlocalized 4.4, 95% CI 3.9–5.1; HRadvanced 8.9, 95% CI 7.5–10.6) and remained markedly increased for up to five years after diagnosis. Dependent on stage of disease and age, 1.4 to 4.7 excess women per 100 with cervical cancer were prolonged users of hypnotics compared to cancer-free women one year after diagnosis. Risk factors for prolonged use of hypnotics were higher age, short education, previous use of antidepressants or anxiolytics, and advanced disease. Conclusions: Women diagnosed with cervical cancer are at increased risk of prolonged use of hypnotics. For the majority, treatment with hypnotics is initiated within the first year after cancer diagnosis, but the rate of first use is increased for up to five years.

KW - Cervical cancer

KW - Cohort study

KW - Epidemiology

KW - Hypnotic use

KW - Late effects

KW - Sleeping problems

U2 - 10.1016/j.ygyno.2022.05.019

DO - 10.1016/j.ygyno.2022.05.019

M3 - Journal article

C2 - 35680430

AN - SCOPUS:85131424776

VL - 166

SP - 300

EP - 307

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -

ID: 318719868